ReviewWorld journal of gastroenterology2006
Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Review in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Postoperative biliary adverse events following orthotopic liver transplantation: assessment with magnetic resonance cholangiography.World journal of gastroenterology · 2014Pooled it
- Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.Journal for immunotherapy of cancer · 2026Trial
- Engineering controlled-release steroid therapeutics: fabrication and molecular design of self-assembled microparticles.Science advances · 2026Article
- Vanished Without a Trace: A Middle-Aged Man With Vanishing Bile Duct Syndrome-A Case Report.Case reports in gastrointestinal medicine · 2026Article
- Bile acids as therapeutic agents.Frontiers in pharmacology · 2025Review
- Acquired ductopenia: an insight into imaging findings.Abdominal radiology (New York) · 2025Review
- Hodgkin lymphoma associated vanishing bile duct syndrome treated successfully with a brentuximab based regimen.BMJ case reports · 2023Article
- Pembrolizumab-induced immune-related sclerosing cholangitis.BMJ case reports · 2023Article
- Histopathological Features Predicting Long-term Clinical Outcomes in Patients with Vanishing Bile Duct Syndrome.Journal of clinical and translational hepatology · 2023Article
- Atypical primary biliary cholangitis results in vanishing bile duct syndrome with cutaneous xanthomas: a case report.Diagnostic pathology · 2022Article
- Vanishing Bile Duct Syndrome in an Adult Patient: Case Report and Review of the Literature.Journal of clinical medicine · 2022Article
- Vanishing Bile Duct Syndrome Associated With Non-Hodgkin's Lymphoma and Hepatitis E Virus Infection.Cureus · 2022Article
- A Case of Vanishing Bile Duct Syndrome after Drug-Induced Liver Injury Caused by Pelubiprofen.Yonsei medical journal · 2020Article
- Transcutaneous Neuromodulation improved inflammation and sympathovagal ratio in patients with primary biliary ssscholangitis and inadequate response to Ursodeoxycholic acid: a pilot study.BMC complementary medicine and therapies · 2020Article
- Review
- Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis.Gastroenterology research and practice · 2019Article
- Recent advances in the management of pruritus in chronic liver diseases.World journal of gastroenterology · 2017Review
- Substitutes for Bear Bile for the Treatment of Liver Diseases: Research Progress and Future Perspective.Evidence-based complementary and alternative medicine : eCAM · 2016Review
- Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.BMJ case reports · 2014Article
- Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature.BMC research notes · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vanishing bile duct syndromes (VBDS) are characterized by progressive loss of small intrahepatic ducts caused by a variety of different diseases leading to chronic cholestasis, cirrhosis, and premature death from liver failure. The majority of adult patients with VBDS suffer from primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Ursodeoxycholic acid (UDCA), a hydrophilic dihydroxy bile acid, is the only drug currently approved for the treatment of patients with PBC, and anticholestatic effects have been reported for several other cholestatic syndromes. Several potential mechanisms of action of UDCA have been proposed including stimulation of hepatobiliary secretion, inhibition of apoptosis and protection of cholangiocytes against toxic effects of hydrophobic bile acids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.